Objective To explore the effect of hydrocortisone sodium succinate on perioperative airway management in bronchial asthma patients. Methods 47 perioperative bronchial asthma patients with artificial airway in Linzhou City People Hospital were enrolled,and they were randomly divided into control group(24 cases) and therapy group(23 cases). Doxofylline 300 mg intravenous(IV)drip per day was given to the patients in both groups,and in therapy group,additionally hydrocortisone sodium succinate 500 mg IV drip per day was applied. The remission of asthma and changes in vital signs,arterial blood gas and respiratory function were observed in both groups. Results There were no significant differences in remission rate and invalid number at 30 minutes after treatment between therapy group and control group(both P>0.05). The remission rate of asthma in therapy group at 1 hour after treatment was significantly higher than that in control group(95.7%vs. 66.7%,P=0.023),the mean remission time was shorter than that in control group(minutes:38.09±15.93 vs. 45.83±18.75,P=0.012),the respiratory rate was lower(beats/min:20.8±2.3 vs. 22.3±3.3,P=0.042),and arterial partial pressure of oxygen〔PaO2(mmHg,1 mmHg=0.133 kPa):83.5±8.9 vs. 77.9±7.4,P=0.028〕,lactate〔Lac(mmol/L):1.87±0.29 vs. 2.09±0.33,P=0.029〕,forced vital capacity〔FVC(L):3.84±0.23 vs. 3.65±0.31,P=0.004〕and forced expiratory volume in 1 second〔FEV1(L):3.34±0.20 vs. 3.16±0.29,P=0.003〕were significantly increased compared with those in control group. But there were no significant differences in heart rate(HR),arterial oxygen saturation(SaO2),pH value,arterial partial pressure of carbon dioxide(PaCO2),FEV1/FVC,and peak expiratory flow (PEF)between the two groups(all P>0.05). Conclusion Hydrocortisone sodium succinate in conjunction with doxofylline can relax the symptom of perioperative bronchial asthma patients with artificial airway faster.

Objective To describe the immunological characteristics of refractory primary biliary cirrhosis compared with the typical patients for more than 1 year's administration of UDCA.Methods Sixty patients treated with UDCA for more than 1 year in our clinic were enrolled into this study.According to the response to UDCA by Paris criteria,patients were divided into refractory group (23 patients) and typical groups (37 patients).The recent peripheral lymphocyte subsets and cytokines of the two groups were tested and analyzed.One-way ANOVA and t test were used for statistical analysis.Results ① One-year treatment after diagnosis,there were no differences between the two groups in the distribution of peripheral lymphocytic subsets,meanwhile,the two groups had higher percentage of B cells,CD4+T cells,CD4+CD28+T cells and CD8+ CD28-T cells than healthy controls respectively.② The serum levels of IL-6 [(0.8±0.9) pg/ml vs (0.3±0.4) pg/ml] and HGF were higher in the refractory group than other groups.Conclusion During the plateau phase,refractory PBC patients have higher serum levels of IL-6 and HGF,which probably suggest that the refractory PBC patients may have severe immunologic disturbance in vivo.

Objective To investigate the effects of eicosapentaenoic acid (EPA) or EPA plus carboplatin on the proliferation and apoptosis of human lung cancer cell line A-549.Methods A-549 cells were cultured by 100 μg/ml carboplatin,80 μg/ml EPA,and their combination for 48 hours.MTT assay was used to determine the effect of EPA,carboplatin,or their combination on the proliferation of human lung cancer cell line A-549.The morphological changes of human lung cancer cell line A-549 were observed using HE staining,and apoptosis of A-549 cells was analyzed by flow cytometry.Results MTT assay showed that the proliferation inhibition rate of A-549 cells cultured with EPA plus carboplatin was 85.20％ ± 5.00％,which was significantly higher than that of cells cultured with 80 μg/ml EPA (32.85％ ± 3.00％,P =0.0001 ) or 100 μg/ml carboplatin (53.25％ ±3.00％,P =0.0013 ).HE staining showed apoptosis in all three groups,whereas the apoptosis rate reached 17.05％ ± 4.00％ in the combination group,which was significantly higher than that in carboplatin group (9.49％ ± 1.00％,P =0.0252).Conclusion EPA may enhance the effects of carboplatin in inhibiting the proliferation and promoting the apoptosis of human lung cancer cell line A-549.

Objective To identify biomarkers in cerebrospinal fluid (CSF) by proteomic technology and develop a diagnostic model for neuropsychiatric lupus (NPSLE).Methods CSF proteomic spectra of 27 patients with NPSLE before and after treatment,and 27 controls including 17 patients with scoliosis,and 10 SLE patients without neuropsychiatric manifestation (non-NPSLE) were generated by matrix assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) combined with weak cationic exchange (WCX) magnetic beads.Data were analyzed with t test,non-parametric Kruskal-Wallis H test or Wilcoxon sign-rank test.A decision tree model for NPSLE classification was built based on the discriminating peaks.In addition,CSF samples of 12 patients with NPSLE,12 patients with lumbar disc herniation and 9 patients with other neurological conditions were employed as blind test group to verify the accuracy of the model.Results Twelve discriminating mass-to-charge (m/z) peaks were identified between NPSLE and controls.The diagnostic decision tree model,built with a panel of m/z peaks 8595,7170,7661,7740 and 5806,recognized NPSLE with the sensitivity and specificity of 92.6％ and 92.6％ based on training group samples,91.7％ and 85.7％ based on blind test group,respectively.Conclusion Potential CSF NPSLE biomarkers are identified by proteomic technology,the novel diagnostic model is sensitive and relatively specific for the diagnosis of NPSLE.

OBJECTIVETo compare the clinical and pathological manifestations of patients with antineutrophil cytoplasmic autoantibodies (ANCA) directed against proteinase 3 (anti-PR3) or myeloperoxidase (anti-MPO).

METHODSOne hundred and forty patients with ANCA were detected for anti-PR3 and anti-MPO by ELISA. The clinical features at presentation, histopathological characteristics and outcome of all patients who were tested positive for anti-PR3 or anti-MPO were analysed.

RESULTSIn anti-PR3 group (n = 21), 16 cases (76.2%) had systemic vasculitis, in which Wegener's granulomatosis prevailed (13 cases, 61.9%). In anti-MPO group (n = 31), 19 cases (61.3%) were diagnosed as systemic vasculitis and 12 cases (38.7%) as microscopic angiitis. For vasculitic patients with anti-PR3 and anti-MPO, the disease duration at diagnosis was 9.6 +/- 2.0 m and 4.4 +/- 0.9 m respectively, P < 0.05; vasculitis activity index (BVAS) and mean number of affected organ were 22.5 +/- 2.1, 5.0 +/- 0.4 and 25.1 +/- 1.7, 4.8 +/- 0.4 respectively, P > 0.05; upper respiratory tract, eye and joint involvements were 11(68.8%), 7(43.8%), 11(68.8%) and 7(36.8%), 2(10.5%), 5(26.3%) respectively, P < 0.05. Although there was no statistical difference in renal involvement between these two groups, patients with serum creatine > 500 micromol/L were more commonly seen in anti-MPO group than in anti-PR3 group, which were 8(42.1%) and 2(12.5%) respectively, P < 0.05. Ten relapses were seen in anti-PR3 group and only 2 in anti-MPO group, but the acute mortality rate in anti-MPO group (5/19, 27.4%) was much higher than that in anti-PR3 group (1/16, 6.3%).

CONCLUSIONSAnti-PR3 and anti-MPO occurred mainly in systemic vasculitis. A large divergence was seen in the disease spectrum between patients with anti-PR3 and those with anti-MPO. In particular, upper respiratory tract, eye and joint involvements, granuloma formation and relapse were more prominent in anti-PR3 patients. By contrast, the anti-MPO patients had a more acute disease onset, more rapid progressive renal involvement and a higher acute mortality rate.

Antibodies, Antineutrophil Cytoplasmic ; analysis ; Autoantibodies ; analysis ; Follow-Up Studies ; Granulomatosis with Polyangiitis ; drug therapy ; immunology ; pathology ; Humans ; Immunosuppressive Agents ; therapeutic use ; Kidney ; pathology ; Myeloblastin ; Peroxidase ; immunology ; Respiratory System ; pathology ; Serine Endopeptidases ; immunology ; Vasculitis ; drug therapy ; immunology ; pathology